결막염 시장 : 질환 유형별, 투여 경로별, 약제 클래스별, 유통 채널별, 지역별
Eye Flu (Conjunctivitis) Market, By Disease Type, By Route of Administration, By Drug Class, By Distribution Channel, By Geography
상품코드
:
1741414
리서치사
:
Coherent Market Insights
발행일
:
2025년 03월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
결막염 시장은 2025년에는 52억 9,000만 달러로 추정되고, 2032년에는 90억 7,000만 달러에 이를 것으로 예상되며, 2025-2032년 CAGR 8%로 성장이 예측되고 있습니다.
| 보고 범위 |
보고서 세부정보 |
| 기준 연도 |
2024년 |
시장 규모(2025년) |
52억 9,000만 달러 |
| 실적 데이터 |
2020-2024년 |
예측 기간 |
2025-2032년 |
| 예측 기간 CAGR(2025-2032년) : |
8.00% |
예측 금액(2032년) |
90억 7,000만 달러 |
결막염은 전 세계적으로 수백만 명이 앓고 있는 일반적인 눈 감염입니다. 결막염은 흰자위 부분을 덮고 눈꺼풀 안쪽을 덮고 있는 얇은 투명한 층인 결막의 염증이 특징입니다. 이 증상은 바이러스 및 세균 감염, 알레르기, 자극물 등 다양한 요인에 의해 발생합니다.
세계의 결막염 시장은 경쟁이 치열하고, 여러 주요 기업이 업계를 지배하고 있습니다. Novartis AG, Allergan, Bausch Health, Santen Pharmaceutical, Johnson & Johnson, Alembic Pharmaceuticals 등이 이 시장의 주요 기업입니다. 이들 기업은 점안약, 연고, 내복약 등 폭넓은 제품과 치료를 제공하고 있습니다.
시장 역학 :
세계 결막염 시장의 성장은 안구 감염 유병률 증가, 눈 건강에 대한 의식 증가, 의료 기술의 진보 등 여러 요인에 의해 견인되고 있습니다. 노년 인구 증가, 알레르기 및 자극물의 발생률 증가도 시장 성장에 기여하고 있습니다.
그러나 세계 결막염 시장의 성장을 저해하는 요인도 있습니다. 치료비의 높은 수준, 개발도상 지역의 의료시설 접근 제한, 대체 치료의 이용 가능성 등입니다. 또, 엄격한 규제 요건이나 특정의 약제에 수반하는 부작용의 리스크라고 하는 과제에도 직면하고 있습니다.
이러한 과제에도 불구하고, 세계의 결막염 시장에는 많은 성장 기회가 있습니다. 효과적이고 안전한 치료법에 대한 수요 증가, 혁신적인 제품의 개발, 신흥 경제 국가에서의 의료 인프라의 확충 등이 가까운 미래 시장 성장의 원동력이 될 것으로 예측됩니다.
본 조사의 주요 특징
- 본 보고서에서는 2024년을 기준연도로 하여 예측 기간(2025-2032년) 동안 시장 규모 및 CAGR 등 세계의 결막염 시장을 상세하게 분석했습니다.
- 또, 다양한 부문에 걸친 잠재적인 수익 기회를 밝혀, 이 시장의 매력적인 투자 제안 매트릭스에 대해서 해설했습니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 인사이트도 제공합니다.
- 본 보고서의 인사이트를 통해 기업의 마케팅 담당자 및 경영진은 장래의 제품 발매, 유형 업그레이드, 시장 확대, 마케팅 전술에 관한 정보에 근거한 의사 결정을 실시할 수 있게 됩니다.
- 세계의 결막염 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해 관계자에 대응하고 있습니다.
- 이해관계자는 세계의 결막염 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정이 용이해집니다.
목차
제1장 조사의 목적 및 전제조건
제2장 시장 전망
- 보고서 설명
- 주요 요약
- 일관된 기회 지도(COM)
제3장 시장 역학, 규제 및 동향 분석
- 시장 역학
- 영향 분석
- 주요 하이라이트
- 규제 시나리오
- 제품 출시 및 승인
- PEST 분석
- Porter's Five Forces 분석
- 합병 및 인수 시나리오
제4장 세계의 결막염 시장 : 코로나바이러스(COVID-19) 팬데믹의 영향
- COVID-19 역학
- 공급측 및 수요측 분석
- 경제에 미치는 영향
제5장 세계의 결막염 시장 : 질환 유형별(2020-2032년)
- 바이러스성 결막염
- 세균성 결막염
- 알레르기성 결막염
- 화학성 결막염
- 기타
제6장 세계의 결막염 시장 : 투여 경로별(2020-2032년)
제7장 세계의 결막염 시장 : 약제 클래스별(2020-2032년)
제8장 세계의 결막염 시장 : 유통 채널별(2020-2032년)
제9장 세계의 결막염 시장 : 지역별(2020-2032년)
- 북미
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 라틴아메리카
- 중동
- 아프리카
제10장 경쟁 구도
- Novartis AG
- Allergan
- Bausch Health
- Santen Pharmaceutical
- Johnson & Johnson
- Alembic Pharmaceuticals
- Akorn Pharmaceuticals
- Alcon
- Pfizer
- Valeant Pharmaceuticals
- Merck & Co.
- Similasan Corporation
- Sun Pharmaceutical Industries
- Prestige Consumer Healthcare
- Lupin Pharmaceuticals
- Alembic Pharmaceuticals
- Aurolab
- Intas Pharmaceuticals
- Sun Pharma
- Cipla
제11장 섹션
AJY
영문 목차
Eye Flu (Conjunctivitis) Market is estimated to be valued at USD 5.29 Bn in 2025 and is expected to reach USD 9.07 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8% from 2025 to 2032.
| Report Coverage |
Report Details |
| Base Year: |
2024 |
Market Size in 2025: |
USD 5.29 Bn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: |
8.00% |
2032 Value Projection: |
USD 9.07 Bn |
Eye flu, also known as conjunctivitis, is a common eye infection that affects millions of people worldwide. It is characterized by inflammation of the conjunctiva, the thin, transparent layer that covers the white part of the eye and lines the inner surface of the eyelids. This condition can be caused by various factors including viral or bacterial infections, allergies, or irritants.
Global eye flu (conjunctivitis) market is highly competitive, with several key players dominating the industry. Novartis AG, Allergan, Bausch Health, Santen Pharmaceutical, Johnson & Johnson, and Alembic Pharmaceuticals are some of the leading companies in this market. These companies offer a wide range of products and treatments for eye flu including eye drops, ointments, and oral medications.
Market Dynamics:
Global eye flu (conjunctivitis) market growth is driven by several factors including the increasing prevalence of eye infections, growing awareness about eye health, and advancements in medical technology. Rising geriatric population and increasing incidence of allergies and irritants also contributes to the market growth.
However, there are certain restraints that may hinder growth of the global eye flu (conjunctivitis) market. These include the high cost of treatment, limited access to healthcare facilities in developing regions, and the availability of alternative treatments. The market faces challenges such as stringent regulatory requirements and the risk of adverse effects associated with certain medications.
Despite these challenges, the global eye flu (conjunctivitis) market presents numerous opportunities for growth. Increasing demand for effective and safe treatments, the development of innovative products, and the expansion of healthcare infrastructure in emerging economies are expected to drive the market growth in the near future.
Key Features of the Study:
- This report provides in-depth analysis of the global eye flu (conjunctivitis) market, including market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, with 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- Key companies covered as a part of this study include Novartis AG, Allergan, Bausch Health, Santen Pharmaceutical, Johnson & Johnson, Alembic Pharmaceuticals, Akorn Pharmaceuticals, Alcon, Pfizer, Valeant Pharmaceuticals, Merck & Co., Similasan Corporation, Sun Pharmaceutical Industries, Prestige Consumer Healthcare, Lupin Pharmaceuticals, Alembic Pharmaceuticals, Aurolab, Intas Pharmaceuticals, Sun Pharma, and Cipla
- Insights from this report would allow marketers and management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global eye flu (conjunctivitis) market report caters to various stakeholders in this industry, including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global eye flu (conjunctivitis) market
Detailed Segmentation:
- By Disease Type
- Viral Conjunctivitis
- Bacterial Conjunctivitis
- Allergic Conjunctivitis
- Chemical Conjunctivitis
- Others
- By Route of Administration
- By Drug Class
- Antibiotics
- Anti-allergy
- Anti-inflammatories
- Combination
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Novartis AG
- Allergan
- Bausch Health
- Santen Pharmaceutical
- Johnson & Johnson
- Alembic Pharmaceuticals
- Akorn Pharmaceuticals
- Alcon
- Pfizer
- Valeant Pharmaceuticals
- Merck & Co.
- Similasan Corporation
- Sun Pharmaceutical Industries
- Prestige Consumer Healthcare
- Lupin Pharmaceuticals
- Alembic Pharmaceuticals
- Aurolab
- Intas Pharmaceuticals
- Sun Pharma
- Cipla
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Disease Type
- Market Snippet, By Route of Administration
- Market Snippet, By Drug Class
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Eye Flu (Conjunctivitis) Market- Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Eye Flu (Conjunctivitis) Market, By Disease Type, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Viral Conjunctivitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Bacterial Conjunctivitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Allergic Conjunctivitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Chemical Conjunctivitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
6. Global Eye Flu (Conjunctivitis) Market, By Route of Administration, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
7. Global Eye Flu (Conjunctivitis) Market, By Drug Class, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Anti-allergy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Anti-inflammatories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Combination
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
8. Global Eye Flu (Conjunctivitis) Market, By Distribution Channel, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
9. Global Eye Flu (Conjunctivitis) Market, By Region, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021-2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Allergan
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bausch Health
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Santen Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Alembic Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Akorn Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Alcon
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Valeant Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Similasan Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Prestige Consumer Healthcare
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Lupin Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Alembic Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Aurolab
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Intas Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sun Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Cipla
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
11. Section
- Research Methodology
- About us
관련자료
